Mariko Ishibashi

1.0k citations
36 papers · 748 indexed · h-index 13
Topics
Multiple Myeloma Research and Treatments (16 papers)Protein Degradation and Inhibitors (7 papers)Peptidase Inhibition and Analysis (7 papers)

In The Last Decade

Mariko Ishibashi

33 papers receiving 742 citations

Peers

Mariko Ishibashi
Comparison fields: 5 of 67
  • Oncology 322
  • Hematology 309
  • Molecular Biology 297
  • Immunology 282
  • Pathology and Forensic Medicine 77
Replace Sunita Badola with:
Sunita Badola United States
C. Gattringer Austria
Minish Jain United States
Edward L. Briercheck United States
Tim Svenstrup Poulsen Denmark
Alexander J. Cole Australia
Qun Jiao United States
Christine‐Ivy Liacos Greece
Shigetoshi Ohga Japan
P A Judson United Kingdom
Mariko Ishibashi relative to Sunita Badola United States Sunita Badola's profile →
Citations per field
00.5×6.1×
Sunita Badola · 1×
Citations per year

Countries citing papers authored by Mariko Ishibashi

Since Specialization
Citations

This map shows the geographic impact of Mariko Ishibashi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mariko Ishibashi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mariko Ishibashi more than expected).

Fields of papers citing papers by Mariko Ishibashi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mariko Ishibashi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mariko Ishibashi. The network helps show where Mariko Ishibashi may publish in the future.

Co-authorship network of co-authors of Mariko Ishibashi

This figure shows the co-authorship network connecting the top 25 collaborators of Mariko Ishibashi. A scholar is included among the top collaborators of Mariko Ishibashi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mariko Ishibashi. Mariko Ishibashi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 0
2 1
3 10
4 2
5 0
6 5
7 1
8 3
9 1
10 78
11 32
12 3
13 41
14 12
15 191
16 15
17 44
18 20
19 86
20 3

About Mariko Ishibashi

Mariko Ishibashi is a scholar working on Hematology, Immunology and Hepatology, having authored 36 papers that have together received 748 indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (16 papers), Protein Degradation and Inhibitors (7 papers) and Peptidase Inhibition and Analysis (7 papers). The work is most often cited by research in Hematology (309 citations), Immunology (282 citations) and Oncology (322 citations). Mariko Ishibashi has collaborated with scholars based in Japan, United States and South Korea. Frequent co-authors include Hideto Tamura, Koiti Inokuchi, Namiko Okuyama, Koji Tamada, Mariko Esumi, Hidemi Takahashi, Kíyoyuki Ogata, Takaji Wakita, Sakae Tanosaki and Asaka Kondo. Their work appears in journals such as Blood, Hepatology and Oncogene.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026